Volume 33 Number 1 (2024)
Empagliflozin May be a Game Changer in Managing Pulmonary Embolism: A Case Report
Husain A1
Mymensingh Med J 2024 Jan; 33 (1): 311-312
PMID: 38163810
Abstract
Pulmonary Embolism (PE) tolls heavy casualty on human lives because it is often misdiagnosed, and patients have limited access to quality care in resource constraint settings. It usually propagates from deep vein thrombosis of lower limbs. A Bangladeshi old lady suddenly developed symptoms on 19 March 2023. She had predisposing conditions like Type-2 Diabetes mellitus, hypertension and knee replacement surgery that made her bedridden for several years. Finding all the available parameters suggestive of PE, she received standard care but failed to have complete remission. When Empagliflozin was added to her treatment plan, she responded very well and got full recovery off her illness. This is the take away of the story.
Keywords: Pulmonary embolism, Thrombosis, Empagliflozin, Anticoagulant
- Former Line Director